Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases.
biomarkers ratio
lymphocytes
monocytes
ovarian cancer
peritoneal carcinomatosis
platelets
Journal
Pleura and peritoneum
ISSN: 2364-768X
Titre abrégé: Pleura Peritoneum
Pays: Germany
ID NLM: 101710063
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
23
10
2022
accepted:
03
05
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Peritoneal metastases of ovarian cancer (PMOC) are common at initial presentation. Cytoreductive surgery (CRS) of curative intent has been proven to be efficient in increasing the overall survival (OS) and the disease-free survival (DFS) of these patients. Nevertheless, CRS is associated with high postoperative morbidity, which makes patient selection a major concern. Appropriate prognostic factors that can predict patient outcomes after surgery are still lacking. Preoperative biomarkers and their ratios have been shown to be predictive of patient prognosis for various solid tumors. We aimed to study their correlation with the prognosis of patients undergoing CRS for PMOC. This retrospective study included patients with PMOC operated by CRS. Preoperative biomarkers and other clinicopathological characteristics were studied to determine their prognostic value in terms OS and DFS. 216 patients were included. Patients with preoperative hemoglobin (Hb) <11.7 g/dL had a poorer prognosis in terms of OS (p=0.0062) and DFS (p=0.0077). Additionally, increased neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) >0.32, and platelet-to-lymphocyte ratio (PLR) >214.5 were associated with worse OS (p=0.022, p=0.0028, and p=0.0018, respectively) and worse DFS (p=0.028, p=0.003, and p=0.019, respectively). Multivariate analysis showed that the variables mentioned above were independent predictive factors for OS and DFS. Preoperative Hb level, NLR, MLR, and PLR are prognostic factors for OS and DFS in PMOC patients operated by curative CRS.
Identifiants
pubmed: 37662604
doi: 10.1515/pp-2022-0199
pii: pp-2022-0199
pmc: PMC10469179
doi:
Types de publication
Journal Article
Langues
eng
Pagination
133-138Informations de copyright
© 2023 the author(s), published by De Gruyter, Berlin/Boston.
Déclaration de conflit d'intérêts
Competing interests: Authors state no conflict of interest.
Références
Transl Oncol. 2017 Feb;10(1):33-39
pubmed: 27888711
Front Biosci. 2006 May 01;11:1585-90
pubmed: 16368539
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503
pubmed: 33421585
Gynecol Oncol. 2014 Mar;132(3):542-50
pubmed: 24462730
Front Oncol. 2020 Sep 17;10:1541
pubmed: 33042799
J Ovarian Res. 2019 Mar 27;12(1):28
pubmed: 30917847
J Cancer. 2020 Mar 4;11(11):3165-3171
pubmed: 32231720
Anticancer Res. 2017 Jul;37(7):3673-3677
pubmed: 28668859
Obstet Gynecol Int. 2015;2015:464123
pubmed: 26106418
Obstet Gynecol Sci. 2020 Jan;63(1):55-63
pubmed: 31970128
BMJ. 2020 Nov 9;371:m3773
pubmed: 33168565
Clin Transl Oncol. 2011 Jul;13(7):499-503
pubmed: 21775277
J Gynecol Oncol. 2012 Oct;23(4):265-73
pubmed: 23094130
J BUON. 2015 May;20 Suppl 1:S64-70
pubmed: 26051335
Oncotarget. 2017 Jul 11;8(28):46414-46424
pubmed: 28423365
AJR Am J Roentgenol. 2016 Jun;206(6):1351-60
pubmed: 27042752
Chin Clin Oncol. 2018 Dec;7(6):59
pubmed: 30509080
BMC Cancer. 2011 Nov 21;11:489
pubmed: 22103888
Eur J Obstet Gynecol Reprod Biol. 2021 Mar;258:382-390
pubmed: 33529973
J Clin Med. 2019 Apr 29;8(5):
pubmed: 31035703
Eur J Surg Oncol. 2018 Jan;44(1):163-169
pubmed: 29198495
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322519
Arch Gynecol Obstet. 2021 Mar;303(3):767-775
pubmed: 33011886
J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101849
pubmed: 32619726